Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Colorcon
Boehringer Ingelheim
AstraZeneca
Medtronic

Last Updated: June 29, 2022

Litigation Details for Pfizer Inc. v. Sandoz Inc. (D. Del. 2013)


✉ Email this page to a colleague

« Back to Dashboard

Pfizer Inc. v. Sandoz Inc. (D. Del. 2013)

Docket See Plans and Pricing Date Filed 2013-06-21
Court District Court, D. Delaware Date Terminated 2016-04-21
Cause 35:271 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand None Referred To
Parties HETERO LABS LIMITED; LUPIN LTD.
Patents 6,858,650; 7,384,980; 7,807,715; 7,855,230; 7,985,772; 8,088,398; 8,338,478; 9,035,031
Attorneys Heinz J. Salmen; Scott Cunning
Firms Morris, Nichols, Arsht & Tunnell; Ross Aronstam & Moritz LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Pfizer Inc. v. Sandoz Inc.
The small molecule drug covered by the patents cited in this case is See Plans and Pricing .
Biologic Drugs cited in Pfizer Inc. v. Sandoz Inc.
The biologic drug covered by the patents cited in this case is See Plans and Pricing .

Details for Pfizer Inc. v. Sandoz Inc. (D. Del. 2013)

Date Filed Document No. Description Snippet Link To Document
2014-07-31 106 (“the ʼ230 patent”), 7,985,772 (“the ʼ772 patent”), and 8,338,478 (“the ʼ478 patent”) (collectively, …infringement of U.S. Patent Nos. 6,858,650 (“the ʼ650 patent”), 7,384,980 (“the ʼ980 patent”), 7,855,230 (“… the ʼ980 patent, claims 1-5 of the ʼ230 patent, claims 4 and 6-8 of the ʼ772 patent, claims 6-…specification of the ʼ650 patent differs from that of the ʼ980 patent and the other three patents-in-suit (collectively…1 of the ʼ650 patent under the guise of claim construction. Claim 1 of the ʼ650 patent is a simple, straightforward External link to document
2014-09-12 123 : U.S. Patent Nos. 7,384,980, 7,855,230, 7,985,772, and 8,338,478. As such, what the inventor describes…of U.S. Patent No. 7,384,980 (“the ʼ980 patent”) (J.A. 2). Claim 1 of the ʼ650 patent is a product…with the ʼ650 patent, and issued as a series of patents, including four of the patents-in-suit here: …the entirety of claim 1 of U.S. Patent No. 6,858,650 (“the ʼ650 patent”) (J.A. 1), and the term “contact…harmony with statutory patent law principles recognizing distinct classes of patentable subject matter, and External link to document
2014-11-23 163 Sandoz. With me is Kristen Venegas from 09:35:31 14 McDermott Will & Emery. And… there are five patents in this 09:41:09 24 lawsuit. Four of those patents are not at issue…compound patents, are 09:41:20 2 shown on the top of the slide there. The patent at issue… is the '650 patent, or what we refer to as the salt 09:41:27 4 patent. That is shown…relationship between the patents in suit, the four compound 09:41:37 7 patents at the top of the External link to document
2014-11-26 165 Infringement of Certain Claims of U.S. Patent Nos. 6,858,650, 7,384,980, 7,855,230, 7,985,772 and 8,338,478, and…2013 21 April 2016 1:13-cv-01110 830 Patent None District Court, D. Delaware External link to document
2014-12-02 168 ORDER CONSTRUING THE TERMS OF U.S. PATENT NOS. 6,858,650 & 7,384,980. Signed by Judge Gregory M. …2013 21 April 2016 1:13-cv-01110 830 Patent None District Court, D. Delaware External link to document
2014-12-09 173 Infringement of Certain Claims of U.S. Patent Nos. 6,858,650, 7,384,980, 7,855,230, 7,985,772 and 8,338,478…2013 21 April 2016 1:13-cv-01110 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Dow
Boehringer Ingelheim
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.